Sign in to view content

Defining a 'Strong' and 'Weak' Response to Anti-VEGF Treatment CI-DME: Retrospective Analysis of 3 DRCR Retina Network Clinical Trials

Sharon D. Solomon, MD

Video
Published 2023

Related

Percentage of Patients Maintained on Quarterly Anti-VEGF Dosing for the Treatment of Neovascular Age-Related Macular Degeneration
David A. Eichenbaum, MD, FASRS
Updates from the Field
2018
Ladder Phase 2 Trial of the Port Delivery System With Ranibizumab (PDS) End of Study Results
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2020
Response to Ranibizumab of Eyes With Pigment Epithelial Detachments, Including Eyes That Developed RPE Tears: Data From the HARBOR Study
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2016

Category: Diabetic Retinopathy

Anti-VEGF

See more